2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-130078
    Ferrous bisglycinate 20150-34-9
    Ferrous bisglycinate is an orally active iron fortificants and therapeutic iron supplements. Ferrous bisglycinate can be used for the research of iron deficiency anemia.
    Ferrous bisglycinate
  • HY-131637
    Desacetyl bisacodyl 603-41-8 99.52%
    Desacetyl bisacodyl is the active metabolite of the laxative bisacodyl. Desacetyl bisacodyl induces epithelial Cl(-) secretion in rat colon and rectum. Desacetyl bisacodyl evokes several effects at the colon or rectum, including increased mucus and chloride secretion.
    Desacetyl bisacodyl
  • HY-135190
    (-)-Cedrene 469-61-4 98.0%
    (-)-Cedrene (α-cedrene) is a major constituent that can be found in essential oils. (-)-Cedrene (α-cedrene) is a natural, orally active ligand of mouse olfactory receptor 23, which induces skeletal muscle hypertrophy in mice. (-)-Cedrene exhibits trypanocidal (Trypanosoma b. brucei) (IC50 = 4.07 μg/mL). (-)-Cedrene is antileukemic in vitro (IC50 = 22.2 μg/mL). (-)-Cedrene has antimicrobial activity against anaerobic bacteria and yeast. (-)-Cedrene exhibits anti-obesity activity.
    (-)-Cedrene
  • HY-143312
    V-0219 878453-71-5 99.90%
    V-0219 is an orally active glucagon-like peptide-1 receptor (GLP-1R) positive allosteric modulator. V-0219 potentiates GLP-1R stimulation, and enhances GLP-1-induced cAMP production and insulin secretion. V-0219 potentiates glucose-dependent insulin secretion. V-0219 improves glucose handling in normal and diabetic rodents. V-0219 can be used for the research of obesity-associated diabetes.
    V-0219
  • HY-14658A
    (S)-Thalidomide 841-67-8 99.52%
    (S)-Thalidomide ((S)-(-)-Thalidomide) is the S-enantiomer of Thalidomide. (S)-Thalidomide has immunomodulatory, anti-inflammatory, antiangiogenic and pro-apoptotic effects. (S)-Thalidomide induces teratogenic effects by binding to cereblon (CRBN) .
    (S)-Thalidomide
  • HY-147372
    SJ000063181 945189-68-4 98.92%
    SJ000063181 is a potent BMP signaling activator. SJ000063181 activates BMP4 and the phosphorylation of SMAD1/5/8 (p-SMAD1/5/8). SJ000063181 induces ventralization in zebrafish embryos.
    SJ000063181
  • HY-148520
    QM295 1241046-32-1 98.53%
    QM295 is an endoplasmic reticulum oxidation 1 (ERO1) inhibitor with selectively reversible thiol reactivity. QM295 can be used for the research of endoplasmic reticulum stress.
    QM295
  • HY-164782
    PT3 2710273-81-5 99.94%
    PT3 is a selective inhibitor of HDAC3 with an IC50 value of 0.25 μM. PT3 exhibits good brain penetration ability and bioavailability upon oral administration. PT3 can be used in the research of Alzheimer’s disease.
    PT3
  • HY-19696B
    Tauroursodeoxycholate dihydrate 117609-50-4 99.96%
    Tauroursodeoxycholate dehydrate is an orally active taurine conjugate of Ursodeoxycholic acid (HY-13771). Tauroursodeoxycholate dehydrate inhibits caspase-3/7, Apoptosis, IRE1α/TRAF2/NF-κB, prevents JNK phosphorylation, inhibits ROS generation, and activates Akt signaling. Tauroursodeoxycholate dehydrate prevents cataract formation, reduces renal tubular damage in type 2 diabetic mice, reduces I/R injury in liver, and inhibits intestinal inflammation and barrier disruption in nonalcoholic fatty liver disease.
    Tauroursodeoxycholate dihydrate
  • HY-B0135A
    Furosemide sodium 41733-55-5 99.87%
    Furosemide sodium is a potent and orally active inhibitor of Na+/K+/2Cl- (NKCC) cotransporter, NKCC1 and NKCC2. Furosemide sodium is also a GABAA receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide sodium acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema.
    Furosemide sodium
  • HY-B0426A
    Olopatadine hydrochloride 140462-76-6 99.83%
    Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4+ and CD8+ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis.
    Olopatadine hydrochloride
  • HY-B1153A
    Glafenine hydrochloride 65513-72-6 99.03%
    Glafenine (Glafenin) hydrochloride is a non-selective, non-steroidal anti-inflammatory drug-based COX-1/COX-2 inhibitor. Glafenine hydrochloride exerts anti-inflammatory, anti-proliferative and anti-cell migration effects by inhibiting the arachidonic acid metabolic pathway and reducing prostaglandin synthesis. Glafenine hydrochloride can induce cell cycle arrest in vascular smooth muscle cells and endothelial cells and reduce the synthesis of the extracellular matrix protein Tenascin. Glafenine hydrochloride can be used in the research of inflammatory-related diseases, vascular restenosis and cystic fibrosis (CF).
    Glafenine hydrochloride
  • HY-D0227A
    THAM hydrochloride 1185-53-1 98.0%
    THAM hydrochloride (Tris HCl) is a biologically inert amino alcohol of low toxicity, which buffers carbon dioxide and acids in vitro and in vivo. THAM hydrochloride is an effective amine compound for pH control in the physiological range.
    THAM hydrochloride
  • HY-N0110B
    Palmatine hydroxide 131-04-4 99.64%
    Palmatine hydroxide is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC50s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine hydroxide can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC50 of 96 μM. Palmatine hydroxide shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities.
    Palmatine hydroxide
  • HY-N0486S
    L-Leucine-d10 106972-44-5 99.0%
    L-Leucine-d10 is the deuterium labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway.
    L-Leucine-d10
  • HY-N0593R
    Deoxycholic acid (Standard) 83-44-3 99.85%
    Deoxycholic acid (Standard) is the analytical standard of Deoxycholic acid. This product is intended for research and analytical applications. Deoxycholic acid (cholanoic acid), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5.
    Deoxycholic acid (Standard)
  • HY-P0201A
    Substance P TFA 148470-19-3 99.34%
    Substance P TFA (Neurokinin P TFA) is a CNS-penetrant neuropeptide, acting as a neurotransmitter and as a neuromodulator in the CNS. The endogenous receptor for substance P is neurokinin 1 receptor (NK1-receptor, NK1R).
    Substance P TFA
  • HY-P10409
    SHLP2 1191923-93-9 99.09%
    SHLP2 (Small humanin-like peptide 2) is a small molecule peptide encoded by mitochondrial DNA, belonging to mitochondria derived peptide. SHLP2 has the activity of regulating apoptosis and inhibits cell death. SHLP2 binds to mitochondrial complex 1. SHLP2 improves mitochondrial metabolism by increasing respiration and biogenesis, reducing ROS, and decreasing mtDNA oxidation. SHLP2 also regulated energy homeostasis through the activation of hypothalamic neurons. SHLP2 can be used in the study of diseases related to mitochondrial dysfunction and anti-aging diseases, such as age-related macular degeneration and Parkinson’s disease.
    SHLP2
  • HY-Y0337R
    L-Cysteine (Standard) 52-90-4 99.89%
    L-Cysteine (Standard) is the analytical standard of L-Cysteine. This product is intended for research and analytical applications. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans.
    L-Cysteine (Standard)
  • HY-103138A
    (Rac)-WAY-161503 75704-24-4 98.49%
    (Rac)-WAY-161503 is a potent, selective, highly affinity 5-HT2C receptor agonist with a Ki of 4 nM and an EC50 of 12 nM. (Rac)-WAY-161503 displays higher affinity for 5-HT2C than 5-HT2A and 5-HT2B receptors. (Rac)-WAY-161503 has anti-obesity and antidepressant effects.
    (Rac)-WAY-161503
Cat. No. Product Name / Synonyms Application Reactivity